Pharmacokinetic trial of Medidur begins:
This article was originally published in Clinica
Alimera Sciences and pSivida have kicked off the first human pharmacokinetic trial of Medidur, the companies' drug-eluting implant for the treatment of diabetic macular oedema. Medidur is injected intra-vitreally and delivers a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years. The new three-year study will also provide information on the location of Medidur FA in the eye after insertion and drug levels in the anterior chamber. Currently in a global phase III trial in around 900 patients, the device is the subject of a co-development agreement between Alimera, of Alpharetta, Georgia, and Perth, Australia-based pSivida.
You may also be interested in...
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.